Radiation oncology company Accuray has been granted US Food and Drug Administration (FDA) approval for the Dose Control System, a new feature for the company’s TomoTherapy system.
The TomoTherapy system enables doses to be precisely applied to target structures while sparing healthy tissue.
Go deeper with GlobalData
The Dose Control System ensures a stable output for treatments with a long duration, including total marrow and total body irradiation.
Accuray president and CEO Euan Thomson said that the Dose Control System can improve the TomoTherapy system’s performance.
